The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) [89] is the biggest trial ever designed in order to define the activity of crizotinib administered for two years compared to placebo in stage Ib (> 4 cm)-IIIA completely resected NSCLC (ALCHEMIST-ALK). Here, ALK is linked to lung cancer.